Bionano Genomics (BNGO) to Release Earnings on Wednesday

Bionano Genomics (NASDAQ:BNGO) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $6.5680 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.78. The firm had revenue of ($20,528.49) million during the quarter, compared to the consensus estimate of $7.88 million. Bionano Genomics had a negative net margin of 92.59% and a negative return on equity of 56.22%.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO opened at $1.24 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.74 and a current ratio of 1.98. Bionano Genomics has a 52 week low of $1.06 and a 52 week high of $5.50. The firm has a market cap of $13.75 million, a PE ratio of -0.26 and a beta of 1.62. The firm’s fifty day moving average is $1.18 and its 200-day moving average is $1.43.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BNGO. HC Wainwright lowered their target price on Bionano Genomics from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Weiss Ratings upgraded Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Bionano Genomics

Several hedge funds and other institutional investors have recently bought and sold shares of BNGO. DRW Securities LLC acquired a new position in Bionano Genomics in the fourth quarter valued at $258,000. Geode Capital Management LLC boosted its position in Bionano Genomics by 148.8% during the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after acquiring an additional 39,928 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Bionano Genomics during the 4th quarter worth about $57,000. Jane Street Group LLC acquired a new stake in Bionano Genomics during the 4th quarter worth about $34,000. Finally, Carret Asset Management LLC raised its position in shares of Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock worth $67,000 after acquiring an additional 19,100 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.